Form 4: Amicus Therapeutics Acquired by BioMarin for $14.50/Share

Director Michael Raab reports the disposal of all Amicus Therapeutics equity holdings following the company's acquisition by BioMarin Pharmaceutical Inc.

Summary

• Director Michael Raab disposed of 115,857 shares of Amicus Therapeutics (FOLD) common stock at $14.50 per share.
• The transaction was executed on April 27, 2026, in connection with the completed acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.
• All outstanding stock options held by the director were cancelled and converted into cash payments based on the $14.50 per share acquisition price minus the respective exercise prices.
• The director no longer holds any beneficial ownership in Amicus Therapeutics following the merger.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a standard regulatory disclosure confirming the finalization of a previously announced acquisition.

Positives

• The acquisition price of $14.50 per share provides a definitive exit valuation for shareholders.
• All restricted stock units and stock options held by the director vested in full upon the consummation of the merger.

Negatives

• The company is no longer an independent publicly traded entity following the acquisition.
• Director and insider equity positions have been liquidated.

Risks

• Integration risks associated with the merger into BioMarin Pharmaceutical Inc.
• Potential loss of independent strategic direction for Amicus Therapeutics' pipeline.

Future Outlook

The company has been acquired by BioMarin Pharmaceutical Inc., and as such, no further independent forward-looking guidance for Amicus Therapeutics is expected.

Management Comments

• The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc.

Industry Context

StockSavvy.ai notes that this acquisition represents a significant consolidation in the rare disease and biotechnology sector, reflecting a trend of larger pharmaceutical companies acquiring specialized biotech firms to bolster their therapeutic portfolios.

Comparison to Industry Standards

• The acquisition follows standard industry practices for biotech M&A, where all-cash deals at a premium are common for companies with established clinical assets.
• The conversion of unvested options and RSUs into cash upon change-of-control is consistent with standard executive compensation agreements in the pharmaceutical industry.

Stakeholder Impact

• Shareholders receive cash consideration for their holdings.
• Employees and management transition to the acquiring entity, BioMarin Pharmaceutical Inc.

Next Steps

• Delisting of Amicus Therapeutics (FOLD) from public exchanges.

Key Dates

Keywords

Amicus Therapeutics, BioMarin Pharmaceutical, Merger, Acquisition, FOLD, Insider Transaction, Form 4